Show simple item record

dc.contributor.authorWasilewski, David
dc.contributor.authorPriego, Neibla
dc.contributor.authorFustero-Torre, Coral
dc.contributor.authorValiente, Manuel 
dc.date.accessioned2019-04-22T11:03:22Z
dc.date.available2019-04-22T11:03:22Z
dc.date.issued2017-12-11
dc.identifier.citationFront Oncol. 2017;7:298.es_ES
dc.identifier.issn2234-943Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7475
dc.description.abstractBrain metastasis, the secondary growth of malignant cells within the central nervous system (CNS), exceeds the incidence of primary brain tumors (i.e., gliomas) by tenfold and are seemingly on the rise owing to the emergence of novel targeted therapies that are more effective in controlling extracranial disease relatively to intracranial lesions. Despite the fact that metastasis to the brain poses a unmet clinical problem, with afflicted patients carrying significant morbidity and a fatal prognosis, our knowledge as to how metastatic cells manage to adapt to the tissue environment of the CNS remains limited. Answering this question could pave the way for novel and more specific therapeutic modalities in brain metastasis by targeting the specific makeup of the brain metastatic niche. In regard to this, astrocytes have emerged as the major host cell type that cancer cells encounter and interact with during brain metastasis formation. Similarly to other CNS disorders, astrocytes become reactive and respond to the presence of cancer cells by changing their phenotype and significantly influencing the outcome of disseminated cancer cells within the CNS. Here, we summarize the current knowledge on the contribution of reactive astrocytes in brain metastasis by focusing on the signaling pathways and types of interactions that play a crucial part in the communication with cancer cells and how these could be translated into innovative therapies.es_ES
dc.description.sponsorshipWe acknowledge members of the Brain Metastasis Group for critically reading the manuscript.This work was supported by MINECO grants MINECO- Retos SAF2014-57243-R (MV), MINECO-Europa Excelencia SAF2015-62547-ERC (MV), IX FERO Grant for Research in Oncology (MV), and Bristol-Myers Squibb-Melanoma Research Alliance Young Investigator Award 498103 (MV). MV is a Ramón y Cajal Investigator (RYC-2013-13365).es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectastrocyte signalinges_ES
dc.subjectbrain metastasises_ES
dc.subjectmetastases therapyes_ES
dc.subjectmicroenvironment heterogeneityes_ES
dc.subjectreactive astrocyteses_ES
dc.subject.meshBrain Diseases, Metabolic es_ES
dc.subject.meshAstrocytes es_ES
dc.titleReactive Astrocytes in Brain Metastasises_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29312881es_ES
dc.format.volume7es_ES
dc.format.page298es_ES
dc.identifier.doi10.3389/fonc.2017.00298es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderBristol-Myers Squibb
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fonc.2017.00298.es_ES
dc.identifier.journalFrontiers in oncologyes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Metástasis Cerebrales_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAFSAF2014-57243-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-62547-ERCes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional